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Aspirin is the most commonly used drug worldwide and has 
known analgesic, antipyretic, anti-inflammatory, and anti-
platelet effects. Despite its wide use, some molecular and 
metabolic mechanisms by which aspirin exerts this diverse 
range of therapeutic effects remain unclear.1 As an anti-
platelet agent, aspirin is employed for both primary preven-
tion of cardiovascular disease and secondary prevention 
of recurrent cardiovascular events following a myocardial 
infarction.2 Aspirin significantly reduces the risk of cardiovas-
cular death, but ~25% of high-risk patients show persistent 
platelet reactivity3,4 (i.e., laboratory aspirin resistance) and 
atherothrombotic events (i.e., clinical aspirin resistance) are 
relatively common2 while on aspirin therapy. Aspirin exerts its 
antiplatelet action by irreversibly inhibiting cyclooxygenase-1 
(COX-1), thereby preventing the conversion of arachidonic 
acid (AA) to the potent platelet agonist thromboxane A2.5 
The mechanisms underlying variability in aspirin response 
are poorly understood. Incomplete COX-1 inhibition has 
been observed in several settings.6,7 However, poor response 
despite complete COX-1 inhibition has also been reported,6,8 
suggesting non–COX-1-mediated mechanisms. To better 
understand these non–COX-1-mediated mechanisms, it is 
important to probe pathways beyond traditional measures 
of aspirin response (e.g., thromboxane B2 levels and AA-
stimulated platelet aggregation). Understanding these non–
COX-1-related mechanisms is critical in order to help identify 
patients who will fail to respond to aspirin so that alternative 
medications may be used to improve clinical outcomes.3,9
Pharmacometabolomics is an emerging field that aims to 
use metabolomics tools to define the mechanisms of action 
for drugs and the biochemical basis for variation in response 
to treatment.10–15 The low-molecular-weight metabolites 
measured with metabolomics in biofluids such as urine or 
blood are the end result of the entire chain of regulatory 
changes that occur in response to treatment. Metabolic 
profiles therefore integrate genetic and environmental influ-
ences and provide unique information that can help explain 
the drug–response phenotype. Several recent studies have 
demonstrated that metabolic profiles can indeed contribute 
to predicting treatment outcomes.16–18
In the present study, we hypothesized that pharmaco-
metabolomics might help identify metabolites influencing 
response to aspirin. Given that amino acids and urea cycle 
amines have previously been associated with cardiovascular 
disease,19,20 we used metabolic profiling targeted for the mea-
surement of metabolites containing an amine functional group 
in serum samples from healthy subjects before and after aspi-
rin therapy. Our specific aims were to characterize the meta-
bolic signature of aspirin exposure and to identify metabolites 
implicated in response variation to aspirin antiplatelet therapy.
RESULTS
Population characteristics and platelet aggregation
Healthy volunteers enrolled in the Heredity and Phenotype 
Intervention (HAPI) Heart Trial were selected for metabolic 
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While aspirin is generally effective for prevention of cardiovascular disease, considerable variation in drug response exists, 
resulting in some individuals displaying high on-treatment platelet reactivity. We used pharmacometabolomics to define 
pathways implicated in variation of response to treatment. We profiled serum samples from healthy subjects pre- and 
postaspirin (14 days, 81 mg/day) using mass spectrometry. We established a strong signature of aspirin exposure independent 
of response (15/34 metabolites changed). In our discovery (N = 80) and replication (N = 125) cohorts, higher serotonin levels 
pre- and postaspirin correlated with high, postaspirin, collagen-induced platelet aggregation. In a third cohort, platelets from 
subjects with the highest levels of serotonin preaspirin retained higher reactivity after incubation with aspirin than platelets 
from subjects with the lowest serotonin levels preaspirin (72 ± 8 vs. 61 ± 11%, P = 0.02, N = 20). Finally, ex vivo, serotonin 
strongly increased platelet reactivity after platelet incubation with aspirin (+20%, P = 4.9 × 10−4, N = 12). These results suggest 
that serotonin is implicated in aspirin response variability.
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profiling based on their response to low-dose aspirin treat-
ment. Supplementary Figure S1 describes the procedure 
for sample selection. Briefly, all 745 subjects who underwent 
a 2-week aspirin intervention study (81 mg/day) as part of 
the initial HAPI study were divided into sex-specific quar-
tiles of collagen-stimulated ex vivo platelet aggregation. To 
maximize the probability of identifying candidate metabolites 
implicated in aspirin response variability, we first selected 
samples from 42 subjects from the first quartile and 38 sub-
jects from the fourth quartile of postaspirin collagen-stimu-
lated platelet aggregation (discovery cohort). The two groups 
were matched for sex and age and had similar body mass 
index. Table 1 presents subject characteristics and platelet 
aggregation.
Before treatment, collagen-induced aggregation was 
higher in subjects from the fourth quartile than in those from 
the first quartile of aspirin response (P = 0.02). By design, 
postaspirin collagen-induced aggregation was significantly 
lower in subjects from the first quartile than in those from the 
fourth quartile (5.5 ± 2.0 vs. 14.2 ± 1.9 Ω, P = 10−14).
Metabolic signature of aspirin exposure
Multilevel principal component analysis21 was used to inves-
tigate the primary sources of variation in serum metabolic 
profiles of subjects from the discovery cohort, using the 35 
metabolites measured. Multilevel principal component analy-
sis plots revealed a trend toward a separation between meta-
bolic profiles before and after aspirin on principal components 
1 and 2, irrespective of gender or quartile (Supplementary 
Figure S2A). This demonstrates that aspirin treatment was 
one of the largest sources of variation in the metabolic pro-
files. As described in the Methods, we subsequently used 
linear mixed models to evaluate simultaneously the effects 
of aspirin exposure, gender, quartile, and their interaction on 
each metabolite level. We identified 19 individual metabolites 
significantly different post- compared to preaspirin exposure 
in those 80 subjects (Table 2).
Significant differences in metabolite levels were observed 
between men and women both pre- and postaspirin 
 (Supplementary Table S1). However, no significant interac-
tion between aspirin treatment and gender was observed, 
demonstrating that aspirin affected metabolite levels similarly 
in men and women.
Differential metabolic signature of aspirin exposure in 
the two extreme quartiles of aspirin response
We evaluated the differences in metabolic signatures in the 
two extreme quartiles of aspirin response and identified four 
Table 1 Subject characteristics in the discovery cohort
First quartile Fourth quartile P value
Demographics
  N 42 38
  Men (%) 50 46 0.83
  Age (year) 43.9 ± 14.3 (20; 75) 43.3 ± 12.4 (23; 70) 0.87
  BMI (kg/m2) 26.6 ± 4.4 (18; 38) 26.1 ± 4.2 (17; 37) 0.38
Platelet aggregation
Collagen (2 µg/ml)
  Before treatment (Ω) 13.2 ± 1.9 (10; 19) 14.2 ± 1.9 (10; 18) 0.02
  After treatment (Ω) 5.5 ± 2.0 (2; 10) 14.2 ± 1.9 (12; 20) 1 × 10−14
  Change (Ω) −7.7 ± 2.1 (−12; −4) 0 ± 2.2 (−6; 5) 3 × 10−14
Arachidonic acid (0.5 mmol/l)
  Before treatment (Ω) 9.3 ± 2.7 (2; 14) 11.3 ± 2.6 (5; 17) 2 × 10−3
  After treatment (Ω) 0.3 ± 1.2 (0; 6) 2 ± 3.4 (0; 13) 5 × 10−3
  Change (Ω) −8.9 ± 3.1 (−14; 1) −9.3 ± 4.2 (−17; 0) 0.5
Data represent mean ± SD (min; max).
BMI, body mass index.
Table 2 Metabolites significantly changed during aspirin exposure
Metabolite HMDB ID Preaspirin Postaspirin change P value q value
glycylglycine HMDB11733 3.4 ± 1.9 1.5 ± 1 ↓ <1 × 10−3 6 × 10−5
l-Aspartic acid HMDB00191 22.8 ± 7.2 15.1 ± 5 ↓ <1 × 10−3 6 × 10−5
O-Phosphoethanolamine HMDB00224 1.1 ± 0.4 1.3 ± 0.4 ↑ <1 × 10−3 6 × 10−5
Serotonina HMDB00259 0.6 ± 0.2 0.7 ± 0.2 ↑ <1 × 10−3 6 × 10−5
l-glutamic acid HMDB00148 51.3 ± 19.1 42.6 ± 19.2 ↓ <1 × 10−3 6 × 10−5
l-Leucine HMDB00687 131.2 ± 18.4 122.1 ± 16.8 ↓ <1 × 10−3 6 × 10−5
l-Phenylalanine HMDB00159 72.2 ± 9.7 63.4 ± 7.7 ↓ <1 × 10−3 6 × 10−5
l-Serine HMDB00187 125.5 ± 17.4 113.9 ± 18.8 ↓ <1 × 10−3 6 × 10−5
Ethanolamine HMDB00149 1.06 ± 0.2 0.94 ± 0.1 ↓ <1 × 10−3 6 × 10−5
glycinea HMDB00123 307.0 ± 76.7 291.7 ± 84.9 ↓ <1 × 10−3 6 × 10−5
Ornithine HMDB00214 81.7 ± 22.1 71.7 ± 17.7 ↓ <1 × 10−3 6 × 10−5
Taurinea HMDB00251 94.1 ± 28.2 81.7 ± 26.7 ↓ <1 × 10−3 6 × 10−5
l-Asparagine HMDB00168 52.1 ± 6.9 50.0 ± 6.4 ↓ 0.003 2 × 10−3
l-Valine HMDB00883 224.5 ± 31.9 215.4 ± 29.8 ↓ 0.004 2 × 10−3
Beta-alanine HMDB00056 7.8 ± 1.1 7.4 ± 1.1 ↓ 0.007 4 × 10−3
l-Lysine HMDB00182 239.7 ± 36.1 228.4 ± 32.9 ↓ 0.01 5 × 10−3
l-Histidine HMDB00177 79.7 ± 9.5 76.5 ± 9.6 ↓ 0.012 5 × 10−3
l-Tyrosine HMDB00158 69.8 ± 10.0 67.4 ± 11.8 ↓ 0.012 5 × 10−3
l-Glutamine HMDB00641 602.5 ± 68.2 584.8 ± 68.0 ↓ 0.015 6 × 10−3
Data represent mean ± SD of metabolite concentrations (µmol/l) for all subjects from the discovery cohort (n = 80). Absolute concentrations could not be deter-
mined for metabolites in italic, so data represent mean ± SD of metabolite levels divided by the mean metabolite level detected in this study. Metabolites in bold 
were significantly changed by aspirin exposure in an independent subset of individuals from the HAPI population (replication cohort, n = 125).
aDisplays a significant exposure × quartile interaction.
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metabolites with significant treatment × quartile interaction: 
alanine (P = 0.003, q = 0.02), taurine (P = 0.01, q = 0.04), gly-
cine (P = 0.03, q = 0.05), and serotonin (P = 0.03, q = 0.05).
Alanine was significantly decreased in subjects from the 
first quartile (P < 10−3, q < 10−3) but not in those from the 
fourth quartile upon aspirin treatment, resulting in lower  levels 
in subjects from the first quartile postaspirin (P = 0.006, q < 
10−3). Subjects from the fourth quartile had higher levels of 
taurine before aspirin (P = 0.005, q = 0.002) that significantly 
decreased upon treatment (P < 10−3, q < 10−3), resulting in 
similar levels in both groups posttreatment. Glycine was sig-
nificantly decreased in subjects from the first quartile only 
upon aspirin (P < 10−3, q < 10−3), resulting in lower postaspirin 
levels in those subjects (P < 10−3, q < 10−3) (Supplementary 
Figure S3).
Interestingly, subjects from the fourth quartile had higher 
levels of serotonin preaspirin (0.66 ± 0.25 vs. 0.53 ± 0.19 
µmol/l, P = 0.02, q = 0.05) and the difference in serotonin 
levels between the two groups increased further postaspi-
rin (0.76 ± 0.28 vs. 0.55 ± 0.18 µmol/l, P < 10−3, q < 10−3) 
(Figure 1a).
Replication cohort
To validate our findings, we profiled serum samples in an 
independent group of 125 HAPI subjects across the entire 
distribution of drug response. This replication set was 
matched for sex, age, and body mass index with our discov-
ery cohort (Supplementary Table S2).
Consistent with our discovery sample, multilevel principal 
component analysis showed a trend toward a separation 
between metabolic profiles pre- and postaspirin exposure in 
all subjects (Supplementary Figure S2B) and 15 individual 
metabolites changed significantly post- compared to preaspi-
rin (Table 2, highlighted in bold), confirming the strong effect 
of aspirin on amine metabolites.
To provide a direct replication of our previous results in our 
discovery cohort, the four metabolites that were related to 
drug response in our discovery sample (i.e., serotonin, tau-
rine, glycine, and l-alanine) were first investigated in the sub-
jects from the two extreme quartiles in this replication cohort. 
Again, serotonin levels were significantly higher in subjects 
from the fourth quartile (n = 19) compared to those from the 
first quartile (n = 19) both pre- and postaspirin (P < 0.001 
for both, Figure 1b). No significant differences in taurine, 
glycine, or l-alanine levels were observed (Supplementary 
Figure S3).
We next investigated whether metabolite levels were corre-
lated to ex vivo agonist-induced platelet aggregation across 
the continuum of aspirin response in all replication subjects 
(n = 125). Pre- and postaspirin serotonin levels correlated 
with postaspirin collagen-induced platelet aggregation (ρ = 
0.39 and P = 9 × 10−6; ρ = 0.38 and P = 1 × 10−5, respectively) 
(Figure 2). Pre- and postaspirin serotonin levels were highly 
correlated to each other (Supplementary Figure S4). Impor-
tantly, serotonin levels did not correlate with AA-induced 
platelet aggregation. Finally, taurine, glycine, l-alanine, or 
any other metabolite did not correlate significantly with AA- or 
collagen-induced platelet aggregation pre- or posttreatment 
(Supplementary Figure S5).
Serotonin as a predictor of on-aspirin platelet reactivity
Because we consistently found that serotonin was associ-
ated with aspirin response evaluated by ex vivo collagen-
induced platelet aggregation in Amish subjects from the 
HAPI study, a genetically and culturally homogeneous 
group, we next sought to investigate whether baseline sero-
tonin levels could help predict which individuals would retain 
high platelet reactivity postaspirin in an independent cohort 
of 38 unrelated healthy subjects from the general popula-
tion (functional cohort 1). We first compared serotonin levels 
in platelet-rich plasma (PRP), platelet-poor plasma (PPP), 
and serum. As expected, PPP serotonin levels were very 
low (Figure 3a), whereas serum and PRP serotonin levels 
were highly correlated (R2 = 0.7, P = 1 × 10−6, Figure 3b), 
demonstrating that serum serotonin mostly reflected platelet-
derived serotonin. However, because serotonin can bind to 
proteins during the coagulation process,22 thereby reducing 
the amount of serotonin in serum, we used PRP in the fol-
lowing experiments. Subjects were divided into quartiles of 
preaspirin PRP serotonin levels, which ranged from 0.37 to 
2.22 nmol/l/106 platelets in subjects from the lowest quartile 
(n = 10) and from 3.26 to 6.56 nmol/l/106 platelets in sub-
jects from the highest quartile (n = 10). Platelet aggregation 
was measured at baseline and after ex vivo aspirin exposure 
(53 µmol/l for 10 min).
Figure 1 Serotonin in the two extreme quartiles of aspirin response. 
Data represent means and 95% confidence intervals of serotonin 
levels before (blue) and after (red) aspirin exposure in the discovery 
cohort (a: first quartile n = 42, fourth quartile n = 38) and in the 
replication cohort (b, first quartile n = 19, fourth quartile n = 19). 
*P < 0.05, ***P < 0.001.
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Before aspirin, no difference was observed between the 
subjects with the highest and the lowest serotonin levels 
preaspirin in AA- or collagen-induced platelet aggregation 
(Figure 3c,d). Postaspirin, AA-induced platelet aggrega-
tion was completely inhibited and no difference was found 
between the two groups (Figure 3c), whereas collagen-stim-
ulated platelet aggregation was inhibited to a lesser extent in 
individuals with higher serotonin levels preaspirin (61 ± 11 vs. 
72 ± 8% respectively, P = 0.02) (Figure 3d).
Using all 38 subjects from this additional cohort, we also 
investigated the correlations between PRP serotonin levels 
and platelet aggregation measures. We observed a positive 
correlation between PRP serotonin levels and postaspirin 
collagen-induced platelet aggregation (ρ = 0.30, P = 0.06; 
Supplementary Figure S6). No significant correlation was 
observed between serotonin and AA-induced platelet aggre-
gation (data not shown).
Effect of serotonin on on-aspirin platelet aggregation
Finally, although serotonin is a well-described weak platelet 
activator,23,24 little is known regarding its action in the context 
of aspirin therapy. Therefore, we evaluated how ex vivo addi-
tion of serotonin to platelets could modify collagen-induced 
platelet aggregation pre- and postaspirin incubation in a fourth 
independent group of 12 healthy subjects (functional cohort 
2). As expected, in the absence of aspirin, addition of sero-
tonin resulted in a slight increase in collagen-induced platelet 
aggregation (+2%, P = 0.01) (Figure 3e). After aspirin incuba-
tion (16.7 µmol/l or 30 min), the effect of serotonin on platelet 
aggregation was significantly and substantially larger (+20%, 
P = 4.9 × 10−4) (Figure 3e). These results demonstrate that 
serotonin potentiated the agonist effects of collagen on platelet 
aggregation more strongly upon aspirin exposure.
DIScUSSIOn
We investigated the metabolic signature of aspirin exposure 
in healthy volunteers using a quantitative mass spectrometry-
based metabolomics platform targeted to the measurement 
of metabolites containing an amine functional group. Our first 
finding was that aspirin induced strong changes in the serum 
metabolic profiles of all subjects, independently of their gen-
der or their response to treatment. Indeed, we observed a 
change in the concentrations of 15 amine metabolites upon 
aspirin exposure in all subjects. These results are in accor-
dance with our previous findings.25 In our previous work, the 
same serum samples were profiled using an untargeted gas 
chromatography–mass spectrometry platform, which pro-
vided a broader coverage of the metabolome than the tar-
geted method used here. Using gas chromatography–mass 
spectrometry, we also observed a strong general signature 
of aspirin exposure on the metabolic profiles of all subjects, 
including significant changes in the level of metabolites 
involved in purine metabolism. Our past and present results 
therefore consistently demonstrate systemic metabolic effects 
of aspirin that are not directly attributed to prostaglandin inhi-
bition. These findings are of utmost importance to unveil new 
biology regarding the mechanisms of action of aspirin. Oral 
Figure 2 Correlation between serotonin and ex vivo agonist-induced platelet aggregation in the replication cohort (N = 125). (a–c) Platelet 
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bioavailability of aspirin is ~50–60% because a fraction of the 
absorbed dose is deacetylated to salicylic acid in plasma and 
liver before entering the systemic circulation. The serum half-
life of aspirin is ~20 min and the fall in aspirin concentration 
is associated with a rapid rise in salicylic acid concentration, 
which is itself renally excreted or further metabolized.26 Our 
present findings highlight the importance of systemic non–
COX-1 mediated pathways in aspirin’s general mechanisms 
of action. Whether aspirin itself or its metabolites disrupt 
these pathways remains to be determined.
Our second major finding was that increased levels of 
serotonin correlated with higher postaspirin platelet reac-
tivity. In humans, serotonin is synthesized only in neurons27 
and in enterochromaffin (intestine) cells28 and platelets are 
the only blood cells capable of transporting serotonin when 
it is released into plasma. In platelets, serotonin is stored 
at high concentrations into dense granules and is secreted 
upon activation. Serotonin is considered to be only a weak 
agonist, which per se does not activate platelets, but dose 
dependently enhances platelet activation induced by other 
 agonists,23 an effect mediated through the binding of secreted 
serotonin to the 5HT2A receptor on the surface of surrounding 
platelets23,29 and through a receptor-independent signaling 
pathway.24 Mice with elevated blood serotonin in the absence 
of other cardiovascular risk factors had a platelet phenotype 
of hyperreactivity.30 In humans, the importance of serotoner-
gic mechanisms in platelet aggregation has been highlighted 
by several studies on selective serotonin reuptake inhibitors 
(SSRIs). SSRIs block the serotonin transporter, thereby 
inhibiting serotonin uptake into neurons as well as into plate-
lets,31 leading to lower platelet serotonin content and reduced 
platelet aggregation.32 These mechanisms might participate 
to the protective role of SSRIs against cardiovascular dis-
ease.33,34 Moreover, epidemiological studies have shown that 
the concomitant use of SSRIs and aspirin increases the risk 
of bleeding compared to each treatment alone.35 Our data 
add to these epidemiological data by suggesting that sero-
tonin may mediate the increased bleeding risk of aspirin plus 
SSRIs, rather than the interaction being purely an additive 
pharmacodynamics effect.
The role of serotonin in cardiovascular disease is not com-
pletely understood, however, it seems that plasma serotonin 
is elevated in a subset a patients with cardiovascular disor-
ders. Vikenes et al.36 have shown for example that plasma 
serotonin was associated with the extent of coronary artery 
disease and the occurrence of cardiac event in patients 
undergoing coronary angiography. Our metabolomics results 
suggest that high serotonin levels are also associated with 
poor response to aspirin antiplatelet therapy, as assessed 
by ex vivo collagen-stimulated platelet aggregation. More-
over, we show that serotonin potentiates collagen-induced 
platelet aggregation significantly more after platelets were 
 incubated with aspirin than before aspirin incubation. These 
ex vivo findings deserve in vivo confirmation but highlight the 
fact that the effect of serotonin on platelets might be further 
enhanced by aspirin.
Figure 3 Ex vivo functional studies of serotonin. Thirty-eight healthy subjects (functional cohort 1) independent from the Heredity and 
Phenotype Intervention study were selected to participate in functional studies. (a,b) Serotonin was measured at fasting in platelet-rich 
plasma (PRP), serum, and platelet-poor plasma (PPP). (c,d) Subjects were separated into four quartiles of PRP serotonin levels. Arachidonic 
acid–stimulated (c) and collagen-stimulated (d) platelet aggregation were measured before (blue) and after (red) incubation of PRP with 
aspirin in subjects with low (N = 10) vs. high (N = 10) baseline serotonin level. (e) Platelets from 12 additional healthy subjects (functional 
cohort 2) were exposed ex vivo to serotonin (1 µmol/l) alone or to serotonin plus aspirin. Data represent means and 95% confidence intervals 
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In our metabolomics cohorts, baseline (preaspirin) sero-
tonin levels were higher in those subjects from the fourth 
quartile of aspirin response. Using a more heterogeneous 
group of healthy volunteers (functional cohort 1), we con-
firmed that platelets from subjects that have high baseline 
serotonin levels retain higher ex vivo collagen-induced reac-
tivity after incubation with aspirin (Figure 3d). Together, our 
results provide preliminary evidence that serotonin might 
help predict those individuals that retain high on-aspirin 
platelet reactivity. It should be noted that we measured sero-
tonin in serum. The measurements of serotonin in serum 
reflect both intraplatelet serotonin and the plasma circulating 
serotonin mostly bound to proteins. Plasma serotonin levels 
are usually very low (0.07 µmol/l, Figure 3a), accounting 
for <15% of serotonin in serum. Thus, the ~20–25% differ-
ence observed in our study between serum serotonin levels 
of subjects from the first and the fourth quartiles of aspirin 
response is most probably driven by differences in intraplate-
let serotonin. Whether plasma serotonin also correlates with 
aspirin response is unknown.
There are many pathways of platelet activation, besides 
stimulation of the thromboxane A2 receptor, including stim-
ulation of the platelet glycoprotein receptors for collagen, 
ADP, van Willebrand factor, thrombin, epinephrine, and 
 serotonin.37 Constitutive or drug-induced enhanced sensitiv-
ity of platelets to pathways that are independent from COX-1 
and not blocked by aspirin might represent one mechanism 
of poor response to aspirin. In poor responders to low-dose 
aspirin in vitro, enhanced sensitivity of platelets to pathways 
of aggregation that do not depend on thromboxane A2, such 
as ADP38 and collagen,39 has already been reported. Here, 
we found that serotonin levels were highly correlated with 
COX-1–independent platelet aggregation (namely collagen-
induced aggregation) but not with AA-induced aggregation, 
therefore supporting the hypothesis that in our population, 
subjects that retain high collagen-induced platelet aggrega-
tion on aspirin also have enhanced sensitivity to serotonergic 
mechanisms and that this phenomenon is independent from 
COX-1 inhibition by aspirin. Consistent with our present find-
ings, Duerschmied et al.40 recently demonstrated that sero-
tonin receptor antagonism improved platelet inhibition in low 
responders to clopidogrel, another widely used antiplatelet 
drug that acts by inhibiting the P2Y12-ADP receptor on the 
platelet surface.
We used healthy volunteers in this study, which is one 
limitation. However, this is advantageous because the HAPI 
subjects underwent a strict drug and supplement washout 
period before treatment, leading to a thorough evaluation 
of aspirin intervention alone. A second limitation is that we 
investigated the interaction between serotonin and aspirin ex 
vivo in our functional cohort 2. Since aspirin is not metabo-
lized within platelets, we therefore do not take into account 
the possible role of aspirin metabolites. Finally, we evaluated 
aspirin response using agonist-induced platelet aggregation. 
Although these tests are widely used surrogate markers that 
evaluate response to antiplatelet therapy41 and have been 
correlated to clinical outcomes,6,42,43 we aim to ultimately pre-
dict the occurrence of cardiovascular events while on therapy. 
Our current findings therefore need to be validated in patients 
with cardiovascular disease.
In conclusion, we successfully demonstrate the use of 
pharmacometabolomics in establishing new metabolic sig-
nature of drug exposure. We demonstrate that low-dose 
aspirin treatment induces profound changes in the meta-
bolic profiles of healthy individuals that cannot be directly 
attributed to COX-1 inhibition. We then show that correlat-
ing metabolic profiles to clinically relevant surrogate end-
points can identify metabolites implicated in variation in drug 
response. Using this approach, we previously demonstrated 
that serum levels of purine metabolites correlated with on-
aspirin platelet reactivity.25 Here, we show that intraplatelet 
levels of serotonin correlate with on-aspirin platelet reactivity. 
Together, our results suggest that certain metabolite levels, 
together with other factors, could contribute to predicting 
aspirin response.
METHODS
HAPI study design and platelet aggregation measures 
Samples for metabolomics profiling were obtained from sub-
jects enrolled in the HAPI study, which has been described 
previously.44 Briefly, participants were adult members of the 
Old Order Amish population from Lancaster County, PA, 
and considered healthy. A total of 745 subjects participated 
in a short-term aspirin intervention where they were given 
81 mg of aspirin for 14 consecutive days.45 Blood samples 
were obtained after an overnight fast and ex vivo platelet 
aggregometry was performed before aspirin therapy and 
again the morning after the last dose by the same techni-
cian as previously described.25,44 Aggregation was induced 
with collagen (2 µg/ml) or AA (0.5 mmol/l). Blood samples for 
serum preparation were allowed to clot at room temperature 
for 15 min, centrifuged at 3,000 rpm for 10 min then immedi-
ately frozen at −80 °C.
Metabolomics
Sample selection. All 745 HAPI subjects were grouped into 
sex-specific quartiles of aspirin response as assessed by 
postaspirin collagen-induced platelet aggregation adjusted 
for age and preaspirin collagen-induced platelet aggregation. 
We specifically used collagen-stimulated platelet aggregation 
instead of AA-stimulated platelet aggregation as a surrogate 
measure of drug response in order to preferentially identify 
non–COX-mediated changes to the metabolome. Only non–
first-degree relatives were selected for metabolic profiling. In 
the discovery cohort, samples originated from 42 subjects 
from the first drug–response quartile and from 38 subjects 
from the fourth drug–response quartile (Supplementary 
Figure S1). In the replication cohort, samples originated from 
19, 46, 41, and 19 subjects from the first, second, third, and 
fourth quartile, respectively.
Mass spectrometry. The liquid chromatography–mass spec-
trometry method used is targeted to the analysis of primary 
and secondary amines. Detailed procedures for metabo-
lomics measurement are provided in the Supplementary 
Methods, but briefly, analysis was performed using AccQ-
Tag derivatization and samples were analyzed by ultra perfor-
mance liquid chromatography–tandem mass spectrometry. 
Thirty metabolites were quantified and four metabolites were 
www.nature.com/psp
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semiquantified because calibration standards were not avail-
able (Supplementary Table S3).
Follow-up functional studies
Two independent cohorts that were not part of the HAPI 
Heart study, referred to as functional cohorts 1 and 2, were 
evaluated to assess the effects of serotonin on aspirin 
response.
Functional cohort 1. Forty healthy participants were 
recruited from Duke University Medical Center. They com-
pleted questionnaires, which assessed for factors that could 
interfere with endogenous serotonin levels (dietary informa-
tion, medication history, and smoking). Two subjects were 
not included in the study because one was pregnant and 
one was on aspirin therapy. Subject characteristics are pre-
sented in Supplementary Table S4.
Whole blood was drawn after an overnight fast using stan-
dard venipuncture technique into sodium citrate (0.105 mol/l, 
3.2%) Vacutainer tubes. These tubes were spun immediately 
at 135 g for 15 min to separate PRP from red cells. Tubes 
were centrifuged further at 2,100 g to obtain PPP. Platelet 
counts of the pooled PRP were determined using a Sys-
mex KX-21N Hematology Analyzer (Sysmex America, Lin-
colnshire, IL) and PRP was adjusted with PPP to 250,000 
platelets/µl. In addition to the sodium citrate tubes, a Vacu-
tainer serum collection tube was obtained during venipunc-
ture. The tube was allowed to clot for at least 30 min and 
centrifuged at 2,100 g to obtain serum.
Serotonin was quantified using reverse phase high-
pressure liquid chromatography with electrochemical 
detection. The mobile phase contained 0.1 mol/l sodium 
phosphate, 0.8 mmol/l octanesulfonic acid, 0.1 mmol/l 
sodium ethylenediaminetetraacetic acid, and 18% metha-
nol, the pH was adjusted to 3.1 and flow rate was 0.7 ml/
min. Samples were quantified with a BAS Epsilon elec-
trochemical detector (Bioanalytical Systems, W. Lafayette, 
IN) with dual 3-mm glassy carbon electrodes (MF-1000) 
set to 0.7 V.
Subjects were divided into quartiles of PRP serotonin con-
centration. Platelet function was evaluated in PRP by the 
same technician using a 470-VS Chrono-Log aggregometer 
pre- and postaspirin incubation (53 µmo/l for 10 min at room 
temperature) after stimulation with collagen (5 µg/ml) or AA 
(0.5 mmol/l), using PPP as a referent. Measures of platelet 
aggregation were compared between the first and the fourth 
quartiles of preaspirin serotonin levels.
Functional cohort 2. PRP was isolated from blood samples 
drawn into 3.2% citrate-anticoagulated tubes from 12 healthy 
individuals who were not on antiplatelet medication. Blood 
samples were deidentified and thus no other clinical infor-
mation was available. Platelet aggregation was measured in 
PRP by the same technician using a PAP8E aggregometer 
(Becton-Dickinson, Franklin Lakes, NJ) before and after ex 
vivo aspirin exposure (16.5 µmol/l for 30 min at 37 °C) fol-
lowing stimulation with collagen (2 µg/ml) ± serotonin (1 µM) 
using PPP as a referent. Collagen and serotonin were pur-
chased from Chrono-Log and Sigma-Aldrich (St Louis, MO), 
respectively.
Statistical analyses. Missing ion intensity values (maximum 
2.5%) were assumed to result from areas falling below the lim-
its of detection and were imputed with the observed minimum 
for that metabolite divided by 2.46 For the four metabolites for 
which absolute concentrations were not obtained, we report 
metabolite response value divided by the mean metabolite 
response value for the metabolite, a scaling that does not 
affect our conclusions. Metabolite response values were log-
transformed before statistical analysis and back-transformed 
for presentation. We assessed the significance of the effects 
of aspirin exposure, gender, and quartile on metabolite level 
using linear modeling and linear mixed modeling47 in Gen-
Stat 14th edition (VSN International, Hemel Hempstead, UK). 
Three models were fitted for each metabolite.




i t i i i, * * * * *
* *
= + + + +
+
α α α α α
α
0 1 2 3 4
5
gender quartile gender
quartile gender quartilei i i i i tt+ + +α δ ε6 * * * ,
(1)
in which i = 1,2…81, yi,t = vector of metabolite concentrations 
for the ith individual at time t; t = time (pre- or postaspirin 
exposure), gender = man or woman, quartile = first or fourth 
quartile of aspirin response, fixed effects; α0…α6 = regres-
sion coefficients; δi = random effect associated with the ith 
individual; εi,t = error term.
The second and third linear models included data before 
and after treatment, respectively:
y = β β β β0 1 2 3+ gender + quartile + gender*quartile   (2)
y =  + gender + quartile + gender*quartile   0 1 2 3γ γ γ γ (3)
The effect of aspirin therapy on metabolite level was consid-
ered significant when P <0.05 for α1. The effect of quartile 
was considered significant before, after and during treatment 
when P <0.05 for β2, γ2, or α5, respectively. We computed a 
false discovery rate value for each P value using the mafdr 
function in Matlab version R2009a (MathWorks, Natick, MA), 
which uses a procedure introduced by Storey.48 q <0.05 was 
considered significant.
Additional analyses are described in the Supplementary 
Methods.
Informed consents. The investigations were approved by the 
Institutional Review Boards of the University of Maryland, 
Baltimore and Duke University, Durham. Informed consents 
were obtained before participation. The HAPI Heart Study 
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Board.
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